NCT05928585View on ClinicalTrials.gov

A Study of Safety and Drug Levels of HIB210 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

June 10, 2024

Study Completion Date

June 10, 2024

Conditions

Immune System DiseasesAutoimmunity

Interventions

DRUG

HIB210

Experimental monoclonal antibody

DRUG

Placebo

Placebo

Trial Locations (1)

33014

HI-Bio Investigational Site, Hialeah

All Listed Sponsors

lead

HI-Bio, A Biogen Company

INDUSTRY